COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; (C-SMART)

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART Study.

A multi-centre Australian trial with four arms aims to evaluate several different immune modulating drugs for prevention and treatment of COVID-19 specifically in the cancer population.

ARM 1 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts.

ARM 2 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus.

ARM 3 is evaluating the effect of Selinexor (vs placebo) on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection.

ARM 4 is evaluating the effect of Lenzilumab (vs placebo) on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.

Participants may become eligible and transition to different arms and treatments if they become exposed to COVID-19 or are hospitalised with an active moderate/severe COVID-19 infection.

It is hoped this research will provide insight into the best practice for prevention and treatment of COVID-19 in cancer patients as emerging standard of care measures are not always suitable to this especially vulnerable population.

Study Overview

• Status: Completed
• Conditions: Cancer; Covid19; Respiratory Viral Infection
• Intervention / Treatment: Drug: Interferon alfa; Drug: Selinexor; Drug: Lenzilumab

• Study Type: Interventional
• Enrollment (Actual): 441
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Rachel Woolstencroft; Phone Number: +61448503643; Email: rachel.woolstencroft@petermac.org
• Study Contact Backup: Name: Megan Crane; Email: CSMART@petermac.org

Study Locations

• Australia
  • New South Wales
    • Westmead, New South Wales, Australia, 2145
      • Westmead Hospital
  • Victoria
    • Fitzroy, Victoria, Australia, 3065
      • St Vincent's Hospital
    • Melbourne, Victoria, Australia, 3000
      • Peter Maccallum Cancer Centre
    • Melbourne, Victoria, Australia, 3084
      • Austin Health
    • Melbourne, Victoria, Australia, 3052
      • Royal Melbourne Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• ARM 1:

  1. Age equal to or greater than 18 years old
  2. Any haematological or solid tumour
  3. Signed written and verbal informed consent
  4. Willingness to inform the study nurse/co-ordinator of COVID-19 testing
  5. Willingness to perform a self-collect nose/throat swab

ARM 2

1. Age equal to or greater than 18 years old.
2. Any haematological or solid tumour
3. Signed written and verbal informed consent
4. Have been exposed to a known COVID-19 case within the last 72 hours, defined by the current Department of Health and Human services such as household contact, 15 minutes of face to face exposure, 2 hours in close space.
5. Willingness to inform the study nurse/co-ordinator of COVID-19 testing
6. Willingness to perform a self-collect nose/throat swab

ARM 3 1. Age equal to or greater than 18 years of age. 2. Any haematological or solid tumour 3. Current or within the last 12 months received cancer related treatment such as chemotherapy, radiotherapy or targeted small molecule, cellular therapy or immune-modulating therapy 4. Signed written and verbal informed consent 5. Laboratory confirmation of SARS-CoV-2 by PCR as per local laboratory assays 6. Hospitalised 7. Symptoms of COVID-19 such as:

1. Fever equal to or greater than 38 degrees Celsius OR
2. Tachypnoea respiratory rate equal to or greater than 20 breaths/min OR

3. Pulse Oxygen saturation (SpO2) equal to or less than 94% 8. Concurrent standard of care antimicrobials, antivirals are allowed. 9. Female and male patients of child bearing potential will use highly effective contraception. In female child bearing potential participants a negative urine pregnancy test will be required.

   ARM 4

   1. Age equal to or greater than 18 years of age.
   2. Any haematological or solid tumour
   3. Current or within the last 12 months received cancer related treatment such as chemotherapy, radiotherapy or targeted small molecule, cellular therapy or immune-modulating therapy
   4. Signed written and verbal informed consent by participant or proxy capable of giving consent
   5. Laboratory virological confirmation of SARS-CoV-2 by PCR as per local laboratory assays and COVID-19 diagnosis prior to randomisation
   6. Hospitalised but has not required mechanical ventilation
   7. Pneumonia diagnosed by chest x-ray or computed tomography (CT) revealing infiltrates consistent with pneumonia and SpO2 equal to or less than 94% on room air or requires low-flow oxygen supplementation or requires high-flow oxygen supplementation or non-invasive positive pressure ventilation (NIPPV).
   8. Has not participated in other clinical trials for COVID-19 using an immunomodulating monoclonal antibody or kinase inhibitor. Note that participants on dexamethasone, corticosteroids, remdesivir, convalescent plasma and/or hydroxychloroquine with or without azithromycin are not excluded from the study. Agents that have received emergency use authorization and/or are considered by the study site to be standard treatment at the institution for COVID-19 are permitted provided the agent is not an immunomodulating monoclonal antibody or kinase inhibitor. Participation in clinical trials with remdesivir or convalescent plasma is permitted provided that all other eligibility criteria are met.
   9. Females of childbearing potential must have a negative serum or urine pregnancy test at screening/baseline. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for 5 months following their last dose of study drug.

   Exclusion Criteria:

   • ARM 1

     1. Previous diagnosis of COVID-19 (microbiologically proven, either symptomatic or asymptomatic)
     2. Have been exposed to a known COVID-19 case within the last 72 hours, defined by the current Department of Health and Human services such as household contact, 15 minutes of face to face exposure, 2 hours in close space.
     3. Any contra-indication to intra-nasal IFN-a such as severe nasal bleeding requiring intervention, nasal malignancy, nasal deformity, radiotherapy to the nasopharynx and/or oropharynx
     4. Pregnant or breast-feeding women, or women who wish to become pregnant during the course of the study
     5. Participant unable to return for regular follow-up
     6. Life expectancy of less than 4 months
     7. Participant already included in another intervention study on the prevention of COVID-19
     8. Currently unwell with influenza-like symptoms - if participant is found to be COVID-19 negative and becomes asymptomatic, they can be reconsidered for participation

   ARM 2

   1. Previous diagnosis of COVID-19 (microbiologically proven, either symptomatic or asymptomatic)
   2. Any contra-indication to intra-nasal IFN-a such as severe nasal bleeding requiring intervention, nasal malignancy, nasal deformity, radiotherapy to the nasopharynx and/or oropharynx
   3. Pregnant or breast-feeding women, or women who wish to become pregnant during the course of the study
   4. Patient unable to return for follow-up
   5. Life expectancy of less than 1 month
   6. Patient already included in another intervention study on the prevention of COVID-19
   7. Currently unwell with influenza-like symptoms

   ARM 3

   1. Unable to take oral medication
   2. Any known allergic reactions to selinexor or concomitant medication-related contra-indications to selinexor.

   3. Severe critical COVID-19 infection defined as:

      1. Requiring invasive or non-invasive mechanical ventilation, ECMO
      2. Anticipated unlikely to survive within 48 hours
   4. In the opinion of the investigator and primary oncologist, participation in the study would not be in the best interests of the participant
   5. Severe renal impairment defined as creatinine clearance (CrCL) < 20ml/min as calculated using the Cockcroft Gault formula
   6. Severe hepatic impairment defined as aspartate transaminase (AST) or alanine transaminase (ALT) > 5 x upper limit of normal (ULN)

   ARM 4

   1. Invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 2. History of pulmonary alveolar proteinosis (PAP). 3. Women of childbearing potential who are pregnant or breastfeeding. 4. Known hypersensitivity to lenzilumab or any of its components. 5 .Use of any FDA-approved anti-IL-6 therapy (eg. tocilizumab, sarilumab, siltukimab), anti-IL-1 therapy (eg. anakinra, canakinumab) or kinase inhibitor (eg.baracitinib, ibrutinib, acalabrutinib) therapy to treat COVID-19 within 8 weeks prior to randomization. Any live vaccine within 8 weeks prior to randomisation. Note that subjects receiving other FDA-approved immunomodulators to treat underlying autoimmune disorders such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, atopic dermatitis, multiple sclerosis, etc. would not be excluded. Participants on corticosteroids or dexamethasone are not excluded from the study. Note: Participants on convalescent plasma, remdesivir and/or hydroxychloroquine with or without azithromycin are not excluded from the study.

   6. Use of GM-CSF agents (e.g., sargramostim) within 8 weeks prior to randomisation.

   7. Expected survival < 24h in the opinion of the investigator. 8. Any condition that, in the opinion of the investigator, is likely to interfere with the safety and efficacy of the study treatment or puts the subject at unacceptably high risk from the study.

   9. Participation in another interventional study of COVID-19

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: prophylaxis; This study arm (arm 1) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts. Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 3 months while the other group will receive a daily placebo intranasal spray for 3 months. Participants will be followed during the 3-month treatment for incidence of COVID-19 and other respiratory infections.	Drug: Interferon alfa; intranasal spray
Experimental: Post-Exposure Prophylaxis; This study arm (arm 2) is evaluating the effect of interferon-alpha on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus. Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive daily interferon-alpha intranasal spray for 7 days (at a higher dose than arm 1) while the other group will receive a daily placebo intranasal spray for 7 days Participants will be followed for 28 days for incidence of COVID-19 and other respiratory infections.	Drug: Interferon alfa; intranasal spray
Experimental: Moderate COVID-19 infection; This study arm (arm 3) is evaluating the effect of Selinexor on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection. Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive oral Selinexor 3 times a week for 2 weeks while the other group will receive oral placebo 3 times a week for 2 weeks Participants will be followed for 60 days to assess effectiveness and safety.	Drug: Selinexor; oral tablet
Experimental: Severe COVID-19 infection; This study arm (arm 4) is evaluating the effect of Lenzilumab on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection. Participants in this study arm are randomly allocated (by chance) to one of two groups. One group will receive intravenous Lenzilumab over 24 hours while the other group will receive placebo intravenously over 24 hours. Participants will be followed for 60 days to assess effectiveness and safety.	Drug: Lenzilumab; intravenous infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)	Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)	3 months from baseline.
incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing	incidence of any upper or lower community acquired respiratory viral infection (define as identification of respiratory viruses such as coronavirus other than SARS-CoV-2, influenza, parainfluenza, respiratory syncytial virus, rhinovirus, adenovirus, human metapneumovirus). assessed using local standard of care testing (e.g. respiratory swabs, saliva and/or blood)	3 months from baseline.
incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .	incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .	28 days from baseline
incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing	incidence of any upper or lower community acquired respiratory viral infection (define as identification of respiratory viruses such as coronavirus other than SARS-CoV-2, influenza, parainfluenza, respiratory syncytial virus, rhinovirus, adenovirus, human metapneumovirus). Assessed using local standard of care testing (e.g. respiratory swabs, saliva and/or blood)	28 days from baseline
incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records	composite outcome: incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records	60 days from baseline
time to clinical improvement or discharge from hospital assessed using medical records	time to clinical improvement (defined as a two point reduction in clinical progress ordinal scale) or discharge from hospital, whichever occurs first. assessed using medical records	28 days from baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ARM 1: Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. Assessed using patient symptom Diary PRO tool	ARM 1, secondary endpoint 1 Duration of acute respiratory/ILI symptoms in case of confirmed respiratory infection during the study period. (composite either COVID-19 or other respiratory viral infection). assessed using a take-home PRO specifically developed and approved for this study entitled "patient symptom Diary". in combination with any relevant medical records.	120 days from baseline
ARM 1: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records	ARM 1, secondary endpoint 2 Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). Assessed using patient medical records	120 days from baseline
ARM 1: Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records	ARM 1, secondary endpoint 3. Time to diagnosis of other respiratory viral infection in case of confirmed other respiratory viral infection diagnosed during the study period (days). assessed using patient medical records	120 days from baseline
ARM 1: Illness severity in case of confirmed COVID-19 diagnosed during the study period using WHO clinical progression scale	ARM 1, secondary endpoint 4 Illness severity in case of confirmed COVID-19 diagnosed during the study period, defined as the maximal score on the World Health Organization (WHO)'s clinical progression scale ranging from 0 (uninfected) to 10 (death)	120 days from baseline
ARM 1: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records	ARM 1, secondary endpoint 5 Incidence of unplanned all-cause hospital admission during the study period. Composite measure: duration of hospital stay if outcome met. assessed using medical records	120 days from baseline
ARM 1: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records	ARM 1, secondary endpoint 6 Incidence of unplanned infection-related hospital admission during the study period. Composite measure: duration of hospital stay if outcome met. assessed using medical records	120 days from baseline
ARM 1: Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR	ARM 1, secondary endpoint 7 Incidence of sero-conversion of SARS-CoV-2 at the end of the study period. assessed using qPCR	120 days from baseline
ARM 1: Incidence of death from any cause during the study period. assessed using patient medical records	ARM 1, secondary endpoint 8 Incidence of death from any cause during the study period. assessed using patient medical records	120 days from baseline
ARM 1: Incidence of testing for COVID-19 during the study period. assessed using medical records	ARM 1, secondary endpoint 9 Incidence of testing for COVID-19 during the study period. Composite measure: frequency of testing if outcome is met. assessed using medical records	120 days from baseline
ARM 2 Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period. assessed with PRO and medical records.	ARM 2: secondary outcome 1. Duration of acute respiratory symptoms in case of confirmed COVID-19 diagnosed during the study period (days). assessed using a take-home PRO specifically developed and approved for this study entitled "patient symptom Diary". in combination with any relevant medical records.	28 days from baseline
ARM 2: Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records	ARM 2: secondary outcome 2. Time to diagnosis of COVID-19 in case of confirmed COVID-19 diagnosed during the study period (days). assessed using medical records	28 days from baseline
ARM 2: Illness severity in case of confirmed COVID-19 diagnosed during the study period. assessed using WHO clinical progression scale.	ARM 2: secondary outcome 3. Illness severity in case of confirmed COVID-19 diagnosed during the study period, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale ranging from 0 (uninfected) to 10 (death)	28 days from baseline
ARM 2: Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.	ARM 2: secondary outcome 4. Incidence of unplanned all-cause hospital admission during the study period. assessed using medical records.	28 days from baseline
ARM 2: Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records	ARM 2: secondary outcome 5 Incidence of unplanned infection-related hospital admission during the study period. assessed using medical records	28 days from baseline
ARM 2: Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR.	ARM 2: secondary outcome 6 Incidence of seroconversion of SARS-CoV-2 at the end of the study period. assessed using qPCR.	28 days from baseline
ARM 2: Incidence of testing for COVID-19 during the study period assessed using medical records	ARM 2: secondary outcome 7. Incidence of testing for COVID-19 during the study period. Composite measure: frequency of testing if outcome is met. assessed using medical records	28 days from baseline
ARM 3: Time to clinical improvement assessed using medical records.	ARM 3: secondary outcome 1 Time to clinical improvement defined as; Resolution of fever - oral temperature < 38oC for 24 hours without antipyretics AND; Respiratory rate < 20 breaths/minute OR; Oxygen saturation > 94% on room air OR; Hospital discharge assessed using medical records	60 days from baseline
ARM 3: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale	ARM 3: secondary outcome 2. Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale ranging from 0 (uninfected) to 10 (death)	60 days from baseline
ARM 3: change to clinical condition assessed with Karnofsky Performance score	ARM 3: secondary outcome 3 change to clinical condition assessed with Karnofsky Performance score	60 days from baseline
ARM 3: Time to progression to severe COVID-19, defined by WHO ordinal scale	ARM 3: secondary outcome 4. Time to progression to severe COVID-19, defined by WHO ordinal scale	60 days from baseline
ARM 3: Time to all-cause mortality	ARM 3: secondary outcome 5 Time to all-cause mortality	60 days from baseline
ARM 3:Duration of hospitalisation assessed using medical records	ARM 3: secondary outcome 6. Duration of hospitalisation. assessed using medical records	at discharge or day 60 whichever is sooner
ARM 3: Duration of COVID-19 symptoms assessed using patient reported symptom diary.	ARM 3: secondary outcome 7 Duration of COVID-19 symptoms assessed using a take-home PRO specifically developed and approved for this study entitled "patient symptom Diary". in combination with any relevant medical records.	60 days from baseline
ARM 3: Duration of oxygen supplementation (days). assessed using medical records.	ARM 3: secondary outcome 8. Duration of oxygen supplementation (days). assessed using medical records.	60 days from baseline
ARM 3: change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR)	ARM 3: secondary outcome 9 change in nasopharyngeal SARS-CoV-2 viral load shedding (assessed via qPCR)	60 days from baseline
ARM 3: Safety and tolerability of selinexor using relevant medical records	ARM 3: secondary outcome 10. Safety and tolerability of selinexor defined as listing and documentation of frequency and severity of adverse effects. Outcome assessed using any/all of medical records, patient reported, vital signs, ECG, imaging, other investigative procedure as per standard local practice.	60 days from baseline
ARM 3: incidence of changes in blood results relevant to clinical improvement assessed using medical records	ARM 3: secondary outcome 11. composite outcome: incidence of changes in blood results relevant to clinical improvement.; Changes in C-reactive protein (CRP); Changes in ferritin level; Changes in lactate dehydrogenase (LDH) level	60 days from baseline
ARM 4: Incidence of all cause death by day 28 and 60	ARM 4: secondary outcome 1 Incidence of all cause death by day 28 and 60 assessed using medical records	day 28 from baseline and day 60 from baseline
ARM 4: Time to all-cause mortality	ARM 4: secondary outcome 2 Time to all-cause mortality assessed using medical records	any time up to 60 days from baseline
ARM 4: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale	ARM 4: secondary outcome 3 - composite outcome: Illness severity of COVID-19, defined as the maximal score on the World Health Organization (WHO)'s clinical progression ordinal scale ranging from 0 (uninfected) to 10 (death); Proportion who have recovered (defined as 0-4); Proportion who had 1 point improvement; Proportion who had 2 point improvement	any time up to 60 days from baseline
ARM 4: Incidence of ARDS assessed using medical records	ARM 4: secondary outcome 4 Incidence of ARDS. assessed using medical records	any time up to 60 days from baseline
ARM 4: incidence of HLH. assessed using medical records	ARM 4: secondary outcome 5 incidence of HLH. assessed using medical records	any time up to 60 days from baseline
ARM 4: Duration of hospitalisation. assessed using hospital medical records.	ARM 4: secondary outcome 6 Duration of hospitalisation. assessed using hospital medical records.	at discharge or by day 60 whichever is sooner
ARM 4: Proportion discharged from hospital. assessed using medical records	ARM 4: secondary outcome 7 Proportion discharged from hospital. assessed using medical records	at discharge
ARM 4: Incidence of mechanical ventilation up to day 28. assessed using medical records	ARM 4: secondary outcome 8. Incidence of mechanical ventilation up to day 28. assessed using medical records	any time up day 28 from baseline
ARM 4: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records	ARM 4: secondary outcome 9 composite outcome: Ventilator-free days and proportion who did not receive invasive mechanical ventilation. assessed using medical records	any time up to 60 days from baseline
ARM 4: Organ failure free days and proportion who did not develop organ failure. assessed using medical records.	ARM 4: secondary outcome 10. composite outcome: Organ failure free days and proportion who did not develop organ failure. assessed using medical records.	any time up to 60 days from baseline
ARM 4: Incidence and duration of ICU admission. assessed using medical records	ARM 4: secondary outcome 11 composite outcome: Incidence and duration of ICU admission. assessed using medical records	at discharge or by day 60 from baseline.
ARM 4: incidence and duration of supplemental oxygen use. assessed using medical records	ARM 4: secondary outcome 12 composite outcome: incidence and duration of supplemental oxygen use. assessed using medical records	any time up to 60 days from baseline
ARM 4: Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours.	ARM 4: secondary outcome 13. Time to clinical improvement defined as National Early Warning Score 2 (NEWS2) of <2 maintained for 24 hours. assessed using medical records	any time up to 60 days from baseline
ARM 4: incidence of non-invasive ventilation. assessed using medical records	ARM 4: secondary outcome 14 incidence of non-invasive ventilation. assessed using medical records	any time up to 60 days from baseline
ARM 4: number of participants alive and off oxygen at day 60. assessed using medical records.	ARM 4: secondary outcome 15. composite outcome: number of participants alive and off oxygen at day 60. assessed using medical records.	any time up to 60 days from baseline
ARM 4: proportion of participants who had improved oxygenation for >48 hours. assessed using medical records	ARM 4: secondary outcome 16 proportion of participants who had improved oxygenation for >48 hours. assessed using medical records	any time up to 28 days from baseline
ARM 4: Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records	ARM 4: secondary outcome 17 Incidence of adverse events based on the national cancer institute CTCAE v5. Assessed using medical records	any time up to day 28 from baseline.
ARM 4: incidence of SAEs based on NCI CTCAE v5 assessed using medical records	ARM 4: secondary outcome 18 incidence of SAEs based on NCI CTCAE v5 assessed using medical records	any time up to 28 days from baseline.
ARM 4: change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR.	ARM 4: secondary outcome 19 change in nasopharyngeal SARS-CoV-2 viral load shedding. assessed using qPCR.	any time up to day 60 from baseline

Collaborators and Investigators

• Sponsor: Peter MacCallum Cancer Centre, Australia

Publications and helpful links

General Publications

• Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

Study record dates

Study Major Dates

• Study Start (Actual): December 17, 2020
• Primary Completion (Actual): November 28, 2022
• Study Completion (Actual): April 19, 2023

Study Registration Dates

• First Submitted: August 30, 2020
• First Submitted That Met QC Criteria: August 30, 2020
• First Posted (Actual): September 1, 2020

Study Record Updates

• Last Update Posted (Actual): August 24, 2023
• Last Update Submitted That Met QC Criteria: August 23, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: cancer; COVID-19
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Virus Diseases; Physiological Effects of Drugs; Anti-Infective Agents; Antiviral Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Immunologic Factors; Interferons; Interferon-alpha; Lenzilumab
• Other Study ID Numbers: Peter Mac ID 20/135

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes